

S 3934

Increasing Access to Biosimilars Act of 2023
Congress: 118 (2023–2025, Ended)
Chamber: Senate
Policy Area: Health
Introduced: Mar 14, 2024
Current Status: Read twice and referred to the Committee on Finance.
Latest Action: Read twice and referred to the Committee on Finance. (Mar 14, 2024)
Official Text: <https://www.congress.gov/bill/118th-congress/senate-bill/3934>

Sponsor

Name: Sen. Cornyn, John [R-TX]
Party: Republican • **State:** TX • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Bennet, Michael F. [D-CO]	D · CO		Mar 14, 2024

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Mar 14, 2024

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
118 HR 1352	Related bill	Dec 17, 2024: Referred to the Subcommittee on Health.

Summary (as of Mar 14, 2024)

Increasing Access to Biosimilars Act of 2023

This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.

Actions Timeline

- Mar 14, 2024: Introduced in Senate
- Mar 14, 2024: Read twice and referred to the Committee on Finance.